MacroGenics Shares Fall 10% After Lorigerlimab Trial Data
Shares fell to $2.02 after trial data for the investigational cancer treatment showed high rates of severe side effects, including one patient death, and a high dropout rate.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.